Rigel Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

REVENUES - Schedule of Product Revenue Allowance and Reserve Categories (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	$ 26,440	$ 15,684
Provision related to current period sales	76,889	63,972
Adjustment related to prior period sales	(5,538)
Credit or payments made during the period	(70,075)	(53,216)
Ending Balance	27,716	26,440
Chargebacks, Discounts and Fees
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	13,374	8,236
Provision related to current period sales	55,327	49,071
Adjustment related to prior period sales	(758)
Credit or payments made during the period	(55,424)	(43,933)
Ending Balance	12,519	13,374
Government and Other Rebates
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	8,343	3,517
Provision related to current period sales	19,032	13,586
Adjustment related to prior period sales	(3,084)
Credit or payments made during the period	(13,902)	(8,760)
Ending Balance	10,389	8,343
Returns
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	4,723	3,931
Provision related to current period sales	2,530	1,315
Adjustment related to prior period sales	(1,696)
Credit or payments made during the period	(749)	(523)
Ending Balance	$ 4,808	$ 4,723